[en] Several successful clinical trials have been conducted in spinal muscular atrophy (SMA) over recent years which have led to the approval of splicing modifiers and gene transfer therapies. With an increasing number of other agents progressing through pre-clinical and clinical development, increasing worldwide clinical trial readiness is becoming essential.SMA Europe initiated a clinical trial readiness project, which included the development of a pilot face-to-face educational-training initiative for clinical specialists and physiotherapists involved in SMA, with an emphasis on the patient perspective. Participants were selected through two surveys and, ahead of the meeting, a mock protocol with specific questions was provided. The initiative involved a series of presentations, role-play and interactive exercises. We describe here our experience and evaluation of this educational-training initiative, emphasising scientific aspects, psychosocial implications and level of satisfaction.From a participant, patient and industry perspective, such training was considered successful and met the objective, which was to improve clinical trial readiness in emerging sites. Resource planning, ethical considerations and communication with patients were identified as three important topics for future training. This initiative highlights the need to develop a training programme to achieve clinical trial readiness across Europe and showcases a collaborative effort with different stakeholders, clinicians, patient advocacy groups and sponsors to address an important issue.
Disciplines :
Pediatrics Neurology
Author, co-author :
Tizzano, Eduardo F; Department of Clinical and Molecular Genetics Hospital Vall d'Hebron, and Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
Christie-Brown, Vanessa; Research Programme Manager, SMA Europe e.V., Freiburg, Germany
Baranello, Giovanni; The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, & Great Ormond Street Hospital NHS Foundation Trust, London, UK
Germanenko, Olga; Patient Representative, Head of SMA Family Foundation Russia & Delegate of SMA Europe e. V., Freiburg, Germany
Gray, Allyson; Paediatric Research Nurse, Great Ormond Street Hospital NHS Trust, London, United Kingdom
Krstic, Marija; Patient Representative, SMA Serbia & Delegate of SMA Europe e.V., Freiburg, Germany
Lilien, Charlotte; MPT: MDUK Oxford Neuromuscular Centre, Oxford, United Kingdom
Patel, Hinal; The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, & Great Ormond Street Hospital NHS Foundation Trust, London, UK
Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford
Scoto, Mariacristina; The Dubowitz Neuromuscular Centre, Great Ormond Street Hospital NHS Foundation Trust, London, UK & NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London
Language :
English
Title :
Clinical Trial Readiness for Spinal Muscular Atrophy: Experience of an International Educational-Training Initiative.
Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24(9):529-33.
Dangouloff T, Botty C, Beaudart C, Servais L, Hilligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723-32.
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J,Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl JMed. 2018;378(7):625-35.
Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 May 17. doi: 10.1001/jamaneurol.2021.1272.
Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Peña LDM, Shieh PB, Smith EC, Kwon JM, Zaidman CM, Schultz M, Feltner DE, Tauscher-Wisniewski S, Ouyang H, Chand DH, Sproule DM, Macek TA, Mendell JR. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284-93. doi: 10.1016/S1474-4422(21)00001-6.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L; FIREFISH Working Group. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021;384(10):915-23. doi: 10.1056/NEJMoa20 09965.
Ramdas S, Servais L. New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307-15.
Peterson I, Cruz R, Fatou S, Stanley A, Jarecki J. The SMA Clinical Trial Readiness Program: Creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet J Rare Dis. 2020;15(1):118.
Peterson I, Cruz R, Sarr F, Stanley AM, Jarecki J. The SMA Clinical Trial Readiness Program: Creation and evaluation of a program to enhance SMA trial readiness in the United States. Orphanet J Rare Dis. 2020;15(1):118. doi: 10.1186/s13023-020-01387-8.
